Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study
Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study
复制标题
DOI：
10.1080/03009740802687455
复制
发表时间：
2009-01-01
影响因子：
2.1
通讯作者：
Eguchi, K.
中科院分区：
文献类型：
--
作者：
Fujikawa, K.;Kawakami, A.;Eguchi, K.
目的：为了确定不同的临床亚群与针对抗155/140-kDa多肽的肌炎特异性自身抗体（MSA）[抗155/140抗体（Ab）]的关联，抗140-kDa多肽（抗140抗体）和抗氨酰tRNA合成酶（ARS抗体）在日本皮肌炎（DM）患者中的应用。我们比较了30例血清学状态包括这些MSA的DM患者的临床特征和短期预后。结果：抗155/140抗体（n=5）、抗140抗体（n=8）和抗ARS抗体（n=7）均不重叠。所有抗155/140 Ab阳性患者（n=5）均合并恶性肿瘤，所有抗140 Ab阳性患者（n=8）均合并恶性肿瘤，表现为快速进行性间质性肺病（ILD）。在6个月的生存率从糖尿病的诊断显着低于在抗140抗体阳性patients than in other patients.Conclusion：这是第一个研究报告，在一个单一的队列糖尿病患者，不同的临床子集分布在抗155/140抗体阳性组，抗140抗体阳性组，或抗ARS抗体阳性组。我们的数据还证实了先前的证据，即抗155/140 Ab与恶性肿瘤有关，抗140 Ab与快速进展的ILD有关。
Objective: To determine the association of distinct clinical subsets with myositis-specific autoantibodies (MSAs) towards anti-155/140-kDa polypeptides [anti-155/140 antibodies (Abs)], anti-140-kDa polypeptides (anti-140 Abs), and anti-aminoacyl tRNA synthetases (ARS Abs) in Japanese patients with dermatomyositis (DM).Methods: We compared the clinical features and short-term prognoses of 30 DM patients whose serological status included these MSAs. The MSAs were determined by immunoprecipitation.Results: Anti-155/140 Abs (n=5), anti-140 Abs (n=8), and anti-ARS Abs (n=7) did not overlap each other. All of the anti-155/140 Ab-positive patients (n=5) were complicated by malignancies, as were all of the anti-140 Ab-positive patients (n=8), who showed rapidly progressive interstitial lung disease (ILD). The survival rate at 6 months from the diagnosis of DM was significantly lower in the anti-140 Ab-positive patients than in the other patients.Conclusion: This is the first study to report, in a single cohort of DM patients, that distinct clinical subsets are distributed in an anti-155/140 Ab-positive group, an anti-140 Ab-positive group, or an anti-ARS Ab-positive group. Our data also confirm previous evidence that anti-155/140 Abs are involved in malignancies and that anti-140 Abs are involved in rapidly progressive ILD.